EVH Evolent Health, Inc.
Services-Management Services · NYSE · SEC CIK 1628908 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY14.1%
TTM net income YoY-296.1%
TTM EPS YoY-187.3%
Revenue 3-yr CAGR9.4%
Net income 3-yr CAGR—
Margins
Gross margin15.0%
Operating margin-18.5%
Net margin-21.7%
FCF margin—
EBITDA margin-13.9%
Returns
ROE-83.6%
ROA-23.0%
ROIC (approx.)-23.0%
Asset turnover1.06x
Leverage & solvency
Liabilities / assets81.0%
Debt / equity2.60x
Current ratio1.26x
Interest coverage-6.23x
Cash quality & payout
Operating cash flow / net income-0.13x
Accruals ratio-25.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q42025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q42024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $725.37M | $652.52M | $496.25M | $468.72M | $479.53M | $444.33M | $483.65M | $646.54M |
| Cost of revenue | $636.95M | $571.68M | $412.47M | $371.47M | $379.76M | $343.94M | $381.18M | $570.83M |
| Gross profit | $88.42M | $80.84M | $83.77M | $97.25M | $99.77M | $100.39M | $102.47M | $75.71M |
| SG&A expense | $73.12M | $68.83M | $72.82M | $72.66M | $77.59M | $75.21M | $78.41M | $47.70M |
| Operating income | -$6.19M | -$9.56M | -$10.60M | -$408.23M | $886,000 | -$1.17M | -$1.62M | -$18.60M |
| Interest expense | $17.00M | $16.86M | $16.87M | $19.01M | $16.48M | $11.60M | $10.38M | $6.72M |
| Pretax income | -$22.45M | -$25.65M | -$25.72M | -$430.81M | -$19.96M | -$20.72M | -$63.15M | -$23.92M |
| Income tax | $1.12M | $2.71M | $910,000 | -$1.68M | $906,000 | -$825,000 | $1.47M | -$1.12M |
| Net income | -$23.57M | -$28.36M | -$26.63M | -$429.13M | -$20.86M | -$19.90M | -$64.62M | -$22.80M |
| EBITDA | $15.30M | $12.01M | $10.96M | -$363.19M | $24.50M | $21.97M | $22.44M | $10.70M |
| EPS (basic) | -0.21 | -0.25 | -0.24 | -3.84 | -0.24 | -0.44 | -0.63 | -0.27 |
| EPS (diluted) | -0.21 | -0.25 | -0.24 | -3.84 | -0.24 | -0.44 | -0.63 | -0.27 |
| Weighted avg. shares (diluted) | 113.07M | 112.54M | 111.91M | — | 114.07M | 115.88M | 115.31M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $148.25M | $115.70M | $142.03M | $151.86M | $116.65M | $151.00M | $246.55M | $178.50M |
| Receivables | $442.77M | $449.12M | $314.16M | $309.86M | $386.56M | $358.76M | $430.50M | $414.68M |
| Current assets | $617.12M | $610.51M | $502.01M | $506.37M | $570.09M | $562.26M | $727.93M | $607.12M |
| PP&E, net | $82.51M | $81.92M | $81.18M | $80.78M | $80.09M | $77.27M | $74.44M | $73.15M |
| Goodwill | $694.42M | $694.43M | $694.43M | $694.48M | $1.08B | $1.14B | $1.14B | $1.14B |
| Intangibles | $539.17M | $554.43M | $569.68M | $584.94M | $623.69M | $651.17M | $667.88M | $680.16M |
| Total assets | $1.96B | $1.97B | $1.88B | $1.90B | $2.45B | $2.46B | $2.65B | $2.54B |
| Current liabilities | $489.94M | $492.83M | $381.24M | $385.26M | $429.93M | $557.52M | $739.10M | $715.50M |
| Short-term debt | — | — | — | $0 | $5.12M | $172.12M | $171.79M | $171.47M |
| Long-term debt | $969.48M | $966.47M | $973.49M | $970.54M | $1.05B | $648.46M | $647.53M | $490.52M |
| Total debt | $969.48M | $966.47M | $973.49M | $970.54M | $1.06B | $820.57M | $819.33M | $661.99M |
| Total liabilities | $1.59B | $1.59B | $1.48B | $1.48B | $1.61B | $1.34B | $1.52B | $1.35B |
| Shareholders' equity | $372.85M | $383.22M | $396.39M | $415.19M | $842.23M | $896.00M | $935.52M | $1.00B |
| Net debt | $821.23M | $850.76M | $831.46M | $818.68M | $943.29M | $669.58M | $572.78M | $483.49M |
| Cash flow statement | ||||||||
| Operating cash flow | $26.38M | -$9.31M | -$984,000 | $48.80M | $15.81M | -$30.33M | $4.57M | -$26.23M |
| Investing cash flow | -$7.06M | -$6.70M | -$6.41M | $82.15M | -$8.76M | -$60.53M | -$13.09M | -$19.93M |
| Financing cash flow | -$4.55M | -$10.99M | -$3.97M | -$93.04M | -$41.81M | -$8.93M | $107.85M | $96.94M |
| Depreciation & amortization | $21.49M | $21.57M | $21.55M | $45.04M | $23.61M | $23.14M | $24.06M | $29.30M |
| Stock-based compensation | $14.80M | $15.20M | $10.65M | $2.40M | $14.68M | $11.58M | $11.08M | -$6.12M |
| Share buybacks | — | — | — | $0 | — | — | — | $0 |
Free plan shows the latest 8 periods; Pro shows all 51 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.